ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation
FDA-approved m6A demethylase inhibitors can inhibit metastasis driven by ZC3H13 deficiency, which reduces m6A methylation of select transcripts involved in migration and invasion, providing potential...
aacrjournals.org